Fayette Discount Drugs has agreed to pay the United States $50,000 in civil penalties after violating the Controlled Substances Act (CSA) for over two years.
The Jefferson County business was accused of failing to maintain complete and accurate records of controlled substances, as well as not fulfilling requirements set by the CSA.
Under the CSA, entities registered with the Drug Enforcement Administration (DEA) who purchase, distribute, dispense, transfer, or sell controlled substances must comply with inventory and documentation requirements, and are subject to compliance audits.
According to court documents, the civil investigation into Fayette Discount Drugs stemmed from a report alleging the diversion of controlled substances.
The investigation revealed that, between June 2020 and July 2022, Fayette Discount Drugs failed to keep complete, timely, and accurate inventories and records regarding the receipt and dispensing of Schedule II, III, IV, and V controlled substances. The substances included hydrocodone, oxycodone, codeine, alprazolam, and testosterone.
As a result of Fayette Discount Drugs’ alleged actions and inactions, thousands of doses of controlled substances could not be accounted for.
“This settlement illustrates the United States Attorney’s Office’s continued commitment to combating the opioid epidemic,” said U.S. Attorney Darren LaMarca. “Part of our strategy is making sure that registered opioid handlers keep accurate records of these highly addictive and extremely dangerous drugs.”